Cocrystal Pharma’s Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online
Cocrystal Pharma, Inc. (COCP)
NASDAQ:AMEX Investor Relations:
cocrystalpharma.com
Company Research
Source: GlobeNewswire
BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management’s participation in the Noble Capital Markets C-Suite Interview Series is now available online. During the 30-minute video interview hosted by Noble Capital Markets Senior Equity Research Analyst Robert LeBoyer, Cocrystal discussed its antiviral drug-discovery and development work and provided program updates. “Cocrystal utilizes a proprietary structure-based technology platform to discover viral inhibitors that address underserved medical needs in very large markets including pandemics and widespread viral infections,” said Sam Lee, Ph.D., interim co-CEO and President. “This powerful platform differentiates Cocrystal’s approach
Show less
Read more
Impact Snapshot
Event Time:
COCP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COCP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COCP alerts
High impacting Cocrystal Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
COCP
News
- Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza [Yahoo! Finance]Yahoo! Finance
- Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaGlobeNewswire
- Cocrystal Pharma, Inc. (NASDAQ: COCP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs [Yahoo! Finance]Yahoo! Finance
- Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsGlobeNewswire
COCP
Earnings
- 11/13/23 - Beat
COCP
Sec Filings
- 5/7/24 - Form DEF
- 5/1/24 - Form 8-K
- 4/26/24 - Form PRE
- COCP's page on the SEC website